Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer
International Journal of Radiation Oncology*Biology*Physics · 2024-12 · 120 (5) · 1332-1343
DOI: 10.1016/j.ijrobp.2024.06.018 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024-12. Verfasst von Donna M Edwards und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemoradiotherapy, Tomography, Emission-Computed, Single-Photon. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: NIH, University of Michigan Rogel Cancer Center.
Abstract (Originalsprache)
PURPOSE: Local failure rates after treatment for locally advanced non-small cell lung cancer (NSCLC) remain high. Efforts to improve local control with a uniform dose escalation or dose escalation to midtreatment positron emission tomography (PET)-avid residual disease have been limited by heightened toxicity. This trial aimed to refine response-based adaptive radiation therapy (RT) and minimize toxicity by incorporating fluorodeoxyglucose-PET (FDG-PET) and ventilation-perfusion single-photon emission computed tomography (SPECT) imaging midtreatment. METHODS AND MATERIALS: A total of 47 patients with stage IIA to III unresectable NSCLC were prospectively enrolled in this single-institution trial (NCT02492867). Patients received concurrent chemoradiation therapy with personalized response-based adaptive RT over 30 fractions incorporating ventilation-perfusion single-photon emission computed tomography and FDG-PET. The first 21 fractions (46.2 Gy at 2.2 Gy/fraction) were delivered to the tumor while minimizing the dose to the SPECT-defined functional lung. The plan was then adapted for the final 9 fractions (2.2-3.8 Gy/fraction) up to a total of 80.4 Gy, based on the midtreatment FDG-PET tumor response to escalate the dose to the residual tumor while minimizing the dose to the SPECT-defined functional lung. Nonprogressing patients received consolidative carboplatin, paclitaxel, or durvalumab. The primary endpoint of the study was ≥ grade 2 lung and esophageal toxicities. Secondary endpoints included time to local progression, tumor response, and overall survival. RESULTS: At 1 year posttreatment, the rates of grade 2 and grade 3 pneumonitis were 21.3% and 2.1%, respectively, with no difference in pneumonitis rates among patients who received and did not receive adjuvant durvalumab (P = .74). Although there were no grade 3 esophageal-related toxicities, 66.0% of patients experienced grade 2 esophagitis. The 1- and 2-year local control rates were 94.5% (95% CI, 87.4%-100%) and 87.5% (95% CI, 76.7%-100%), respectively. Overall survival was 82.8% (95% CI, 72.6%-94.4%) at 1 year and 62.3% (95% CI, 49.6%-78.3%) at 2 years. CONCLUSIONS: Response-based adaptive dose-escalation accounting for tumor change and normal tissue function during treatment provided excellent local control, comparable toxicity to standard chemoradiation therapy, and did not increase toxicity with adjuvant immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
- Department of Biostatistics, University of Michigan, Ann Arbor, Michigan.
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Biostatistics, University of Michigan, Ann Arbor, Michigan.
- Department of Medicine, Pulmonology, University of Michigan, Ann Arbor, Michigan.
- Department of Radiology, University of Michigan, Ann Arbor, Michigan.
- Department of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, Michigan.
Förderung
- NIH
- University of Michigan Rogel Cancer Center
Zitieren
APA
Edwards, D. M., Schonewolf, C. A., Rice, J. D., Schipper, M., Haken, R. K. T., Matuszak, M., Balter, J., Jarema, D., Arenberg, D. A., Piert, M., Qin, A., Kalemkerian, G. P., Schneider, B. J., Ramnath, N., Chapman, C. H., Elliott, D. A., Lawrence, T. S., Hearn, J., Hayman, J. A., & Jolly, S. (2024). Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics, 120(5), 1332-1343. https://doi.org/10.1016/j.ijrobp.2024.06.018
Vancouver
Edwards DM, Schonewolf CA, Rice JD, Schipper M, Haken RKT, Matuszak M, et al. Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 2024;120(5):1332-1343. doi:10.1016/j.ijrobp.2024.06.018
BibTeX
@article{Edwards2024,
author = {Edwards, Donna M and Schonewolf, Caitlin A and Rice, John D and Schipper, Matthew and Haken, Randall K Ten and Matuszak, Martha and Balter, James and Jarema, David and Arenberg, Douglas A and Piert, Morand and Qin, Angel and Kalemkerian, Gregory P and Schneider, Bryan J and Ramnath, Nithya and Chapman, Christina H and Elliott, David A and Lawrence, Theodore S and Hearn, Jason and Hayman, James A and Jolly, Shruti},
title = {Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
volume = {120},
number = {5},
pages = {1332--1343},
doi = {10.1016/j.ijrobp.2024.06.018}
}
EUVIMED